The U.S. government is taking steps to lower drug prices by applying pressure on pharmaceutical companies and European nations. This approach is part of a broader effort to make prescription medications more affordable for American patients, who often face high costs for essential treatments. The administration is exploring various strategies, including encouraging the production of generic alternatives and negotiating directly with manufacturers to secure lower prices. One of the key areas of focus is the use of international reference pricing, a method where the U.S. looks to drug prices in other countries to set its own. This practice has been controversial, as some manufacturers argue it undermines innovation by reducing potential profits. European countries, particularly those in the European Union, have been targeted due to their generally lower drug prices compared to the U.S. The push for lower prices may have unintended consequences, especially regarding access to new and innovative medicines. Some experts warn that if manufacturers feel their profits are being unfairly limited, they may reduce investment in research and development. This could lead to fewer new drugs being developed or delayed availability in the U.S. and other markets. While the goal of making medications more affordable is widely supported, the methods used to achieve this remain a topic of debate. Balancing the need for lower prices with the incentives for innovation is a complex challenge that policymakers are still working to address.